Enanta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Enanta Pharmaceuticals' es Jay Luly , nombrado en Jul 2003, tiene una permanencia de 20.75 años. compensación anual total es $7.86M, compuesta por 9.6% salario y 90.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.52% de las acciones de la empresa, por valor de €8.97M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 7.4 años, respectivamente.

Información clave

Jay Luly

Chief Executive Officer (CEO)

US$7.9m

Compensación total

Porcentaje del salario del CEO	9.6%
Permanencia del CEO	20.8yrs
Participación del CEO	3.5%
Permanencia media de la dirección	3.4yrs
Promedio de permanencia en la Junta Directiva	7.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jay Luly en comparación con los beneficios de Enanta Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$132m
Dec 31 2023	n/a	n/a	-US$138m
Sep 30 2023	US$8m	US$755k	-US$134m
Jun 30 2023	n/a	n/a	-US$132m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	n/a	n/a	-US$121m
Sep 30 2022	US$7m	US$725k	-US$122m
Jun 30 2022	n/a	n/a	-US$120m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$101m
Sep 30 2021	US$5m	US$693k	-US$79m
Jun 30 2021	n/a	n/a	-US$84m
Mar 31 2021	n/a	n/a	-US$74m
Dec 31 2020	n/a	n/a	-US$58m
Sep 30 2020	US$5m	US$667k	-US$36m
Jun 30 2020	n/a	n/a	US$2m
Mar 31 2020	n/a	n/a	US$24m
Dec 31 2019	n/a	n/a	US$34m
Sep 30 2019	US$4m	US$642k	US$46m
Jun 30 2019	n/a	n/a	US$65m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	n/a	n/a	US$86m
Sep 30 2018	US$4m	US$611k	US$72m
Jun 30 2018	n/a	n/a	US$81m
Mar 31 2018	n/a	n/a	US$52m
Dec 31 2017	n/a	n/a	US$34m
Sep 30 2017	US$4m	US$581k	US$18m

Compensación vs. Mercado: La compensación total de Jay($USD7.86M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD705.27K).

Compensación vs. Ingresos: La compensación de Jay ha aumentado mientras la empresa no es rentable.

CEO

Jay Luly (67 yo)

20.8yrs

Permanencia

US$7,856,698

Compensación

Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Luly	President	20.8yrs	US$7.86m	3.51% $ 9.1m
Paul Mellett	Senior VP of Finance & Administration and CFO	20.7yrs	US$2.85m	0.35% $ 917.2k
Yat Or	Senior VP of Research & Development and Chief Scientific Officer	24.5yrs	US$2.97m	1.66% $ 4.3m
Nathaniel Gardiner	Consultant	less than a year	US$2.86m	0.43% $ 1.1m
Brendan Luu	Senior Vice President of Business Development	3.3yrs	US$2.58m	0.10% $ 267.2k
Jennifer Viera	Senior Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Matthew Kowalsky	Chief Legal Officer	less than a year	sin datos	sin datos
Tara Kieffer	Senior Vice President of New Product Strategy & Development	3.4yrs	US$2.10m	0.11% $ 273.7k
Scott Rottinghaus	Senior VP & Chief Medical Officer	1.8yrs	US$4.84m	0.038% $ 98.5k

3.4yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 9EP se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Luly	President	20.8yrs	US$7.86m	3.51% $ 9.1m
Mark Foletta	Independent Director	3.9yrs	US$331.41k	0% $ 0
Bruce Leonard Carter	Independent Non-Executive Chairman	10.5yrs	US$353.91k	0% $ 0
Terry Vance	Independent Director	12.9yrs	US$333.91k	0.027% $ 71.1k
Kristine Peterson	Independent Director	6.7yrs	US$326.41k	0% $ 0
Yujiro Hata	Independent Director	2.8yrs	US$318.91k	0% $ 0
Lesley Russell	Independent Director	7.5yrs	US$321.41k	0% $ 0

7.5yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 9EP se considera experimentada (7.4 años de antigüedad promedio).

Enanta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold €129k worth of stock

President recently sold €65k worth of stock

Insufficient new directors

Recent updates

Enanta Pharmaceuticals, Inc. to Report Q3, 2024 Results on Aug 05, 2024

Second quarter 2024 earnings released: US$1.47 loss per share (vs US$1.79 loss in 2Q 2023)

Enanta Pharmaceuticals, Inc. to Report Q2, 2024 Results on May 06, 2024

Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer

First quarter 2024 earnings released: US$1.58 loss per share (vs US$1.39 loss in 1Q 2023)

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold €129k worth of stock

President recently sold €65k worth of stock

Full year 2023 earnings released: US$6.38 loss per share (vs US$5.91 loss in FY 2022)

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

New major risk - Share price stability

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.86 loss per share (vs US$1.53 loss in 3Q 2022)

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

New major risk - Share price stability

Insufficient new directors

Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Second quarter 2023 earnings released: US$1.79 loss per share (vs US$1.64 loss in 2Q 2022)

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: US$1.39 loss per share (vs US$1.48 loss in 1Q 2022)

Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023

Full year 2022 earnings released: US$5.91 loss per share (vs US$3.92 loss in FY 2021)

Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023

Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022

Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.19 loss in 3Q 2021)

Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth-Defensive Index

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Second quarter 2022 earnings released: US$1.64 loss per share (vs US$1.09 loss in 2Q 2021)

Enanta Pharmaceuticals, Inc. to Report Q2, 2022 Results on May 09, 2022

Enanta Pharmaceuticals, Inc. Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. announced delayed 10-Q filing

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Enanta Pharmaceuticals, Inc. to Report Q1, 2022 Results on Feb 08, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Director Yujiro Hata has joined 3rd company board

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Third quarter 2021 earnings released: US$1.19 loss per share (vs US$0.71 loss in 3Q 2020)

Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™

Enanta Pharmaceuticals, Inc. Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients

Second quarter 2021 earnings released: US$1.09 loss per share (vs US$0.30 loss in 2Q 2020)

Enanta Pharmaceuticals Reports Positive Data from Part 2 of Its Phase 1B Study of Edp-514 in Chronic Hepatitis B Virus Patients on Treatment with A Nucleoside Reverse Transcriptase Inhibitor

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.68 profit in 1Q 2020)

Revenue beats expectations

Enanta Pharmaceuticals, Inc. Provides Study Results

Enanta Pharmaceuticals, Inc. Appoints Brendan Luu as Senior Vice President, Business Development

New 90-day high: €39.80

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2021

Enanta Pharmaceuticals Announces the Appointment of John P. Devincenzo, M.D. as Vice President of Translational Virology

Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development

Enanta Pharmaceuticals, Inc. Announces Resignation of George Golumbeski as Director

New 90-day low: €34.80

Revenue misses expectations

Full year 2020 earnings released: US$1.81 loss per share

Enanta Pharmaceuticals, Inc. to Report Q1, 2021 Results on Feb 08, 2021

New 90-day low: €36.40

New 90-day low: €37.60

Third quarter earnings released

Third quarter earnings released

Enanta Pharmaceuticals, Inc. to Report Q4, 2020 Results on Nov 23, 2020